Literature DB >> 11641417

Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies.

M Schmidt1, Y Lu, J M Parant, G Lozano, G Bacher, T Beckers, Z Fan.   

Abstract

In this study, the differential role of the cyclin-dependent kinase (CDK) inhibitors p21(Waf1) and p27(Kip1) in cell cycle regulation was proposed for use in screening natural or synthetic compounds for cell cycle-dependent (particularly M phase-dependent) antineoplastic activity. p21(Waf1) or p27(Kip1) was ectopically expressed with an ecdysone-inducible mammalian expression system in a human colon adenocarcinoma cell line. Induction of p21(Waf1) or p27(Kip1) expression inhibited the activities of CDK2 and completely arrested cells at G(1) phase of the cell cycle by p27(Kip1) and at G(1) and G(2) phases by p21(Waf1). We examined the sensitivity of these cells to several antineoplastic agents known to be cell cycle-dependent or -independent. Substantially increased resistance to cell cycle-dependent antineoplastic agents was found in the cells when the expression of p21(Waf1) or p27(Kip1) was induced. In contrast, only a desensitization to cell cycle-independent antineoplastic agents was found in the cells arrested by p21(Waf1) or p27(Kip1). Because p21(Waf1) induces an additional block at G(2) phase that inhibits cell entry into M phase, we further examined the difference between p21(Waf1)- and p27(Kip1)-induced cells in their sensitivity to D-24851, a novel M phase-dependent compound. We found that induction of p21(Waf1) after exposure of the cells to D-24851 conferred stronger resistance than did induction of p27(Kip1). Taken together, our results suggest that the differential effect of p21(Waf1) and p27(Kip1) on cell cycle regulation may be advantageous for screening chemical libraries for novel antineoplastic candidates that are cell cycle-dependent, and M phase-dependent in particular.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11641417     DOI: 10.1124/mol.60.5.900

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  Modeling tumor microenvironments using custom-designed biomaterial scaffolds.

Authors:  Zen Liu; Gordana Vunjak-Novakovic
Journal:  Curr Opin Chem Eng       Date:  2016-02       Impact factor: 5.163

2.  Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes.

Authors:  Chih-Jian Lih; Wensheng Wei; Stanley N Cohen
Journal:  Genes Dev       Date:  2006-07-17       Impact factor: 11.361

3.  Dammarane-type triterpene ginsenoside-Rg18 inhibits human non-small cell lung cancer A549 cell proliferation via G1 phase arrest.

Authors:  Dong-Gyu Leem; Ji-Sun Shin; Kyung-Tack Kim; Sang Yoon Choi; Myung-Hee Lee; Kyung-Tae Lee
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

Review 4.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 5.  The tumor microenvironment is a dominant force in multidrug resistance.

Authors:  Ana Luísa Correia; Mina J Bissell
Journal:  Drug Resist Updat       Date:  2012-02-13       Impact factor: 18.500

Review 6.  Structure and function of the solid tumor niche.

Authors:  Elisabeth A Pedersen; Yusuke Shiozawa; Anjali Mishra; Russell S Taichman
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

7.  A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis.

Authors:  M Schmidt; S Hövelmann; T L Beckers
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

Review 8.  Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer.

Authors:  Jermaine Coward; Angus Harding
Journal:  Front Oncol       Date:  2014-05-26       Impact factor: 6.244

9.  Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells.

Authors:  Ting La; Song Chen; Tao Guo; Xiao Hong Zhao; Liu Teng; Dandan Li; Michael Carnell; Yuan Yuan Zhang; Yu Chen Feng; Nicole Cole; Alexandra C Brown; Didi Zhang; Qihan Dong; Jenny Y Wang; Huixia Cao; Tao Liu; Rick F Thorne; Feng-Min Shao; Xu Dong Zhang; Lei Jin
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.